Navigation Links
BioVascular, Inc. Expands Executive Team
Date:2/26/2008

SAN DIEGO, Feb. 26 /PRNewswire/ -- BioVascular, Inc., a company focused on developing novel therapies targeting platelet-mediated diseases, today announced that it appointed Christopher M. Bussineau, Ph.D., to the position of vice president of pharmaceutical operations and Eric Karpinski to the position of vice president, business development and nonvascular operations.

"Dr. Bussineau and Mr. Karpinski each bring skill and experience to BioVascular that will allow us to advance our business objectives," said John Parrish, CEO of BioVascular. "With continuing clinical progress in our two compounds, we will be looking to Mr. Karpinski to advance partnership discussions. Dr. Bussineau will be invaluable for establishing the infrastructure needed for further clinical development and eventual commercialization."

Dr. Bussineau brings relevant experience to BioVascular in the areas of process development as well as clinical and commercial manufacturing. Prior to joining BioVascular, Dr. Bussineau served as vice president and general manager of Cambrex Bio Science Baltimore. Before that, he was senior director of technical operations for the Biopharmaceutical Division of Chiron Corporation, acquired by Novartis in 2006. Dr. Bussineau holds a Ph.D. in chemical engineering from Rice University and a B.A. in chemistry from the University of California, San Diego.

Mr. Karpinski has extensive experience in business development, venture financing and strategic planning in the biopharma industry. He joined BioVascular after six years as a venture capitalist with Forward Ventures where he drove the diligence and supported companies in the portfolio including Hypnion, sold to Eli Lilly for $315M; Novacardia, sold to Merck for $350M; Predix, sold to Epix Medical; and Adiana, sold to Cytyc. Prior to working at Forward Ventures, Mr. Karpinski held business development and strategic planning roles at Genentech, Epix Medical and the pharmaceutical consulting practice of Arthur D. Little. Mr. Karpinski holds an M.B.A. from The Wharton School of Business at the University of Pennsylvania, and he earned a B.S. in biochemistry from Brown University.

"Our leadership team has already logged an impressive history of successful company development, and with several clinical trials completed or underway at BioVascular; we are well on the path to continued success," noted Mr. Parrish. "I look forward to working with each team member in helping BioVascular shape what looks to be a very strong future."

About BioVascular, Inc.

BioVascular is a privately-held, cardiovascular and vascular disease focused company, dedicated to developing novel therapeutics for platelet- mediated disorders. Started in 2005, the company is leveraging its exclusive rights to two clinical stage cardiovascular compounds with differentiated mechanisms of action to become a leading specialty therapeutics company. BioVascular's most advanced clinical compound, saratin, is currently being studied in two Phase I/II clinical trials for vascular graft failures due to intimal hyperplasia. The company recently acquired the full worldwide rights to BVI-007, which reduces platelet numbers without impairing platelet function.


'/>"/>
SOURCE BioVascular, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. ATS Medical Expands Open Pivot Heart Valve Offerings
2. SAFC Expands Hi-Potency API Manufacturing and Introduces Solid-Form Testing at Its Madison Facility
3. BioLife Solutions Expands Scientific Advisory Board
4. Elekta To Showcase Innovations in Radiotherapy and Unveil New Product That Expands Cancer Treatment Availability
5. SAFC Expands European Commercial Manufacturing and Storage Capacities With $10 Million Investment
6. Pharsight Expands Strategic Consulting Services Team
7. Validus Pharmaceuticals Expands Product Portfolio with Acquisition of Bipolar Drug: Equetro(R)
8. Serica Technologies Expands Facilities in Massachusetts, Combines State-Of-The-Art Textile Engineering and Biomedical Manufacturing
9. AQUISS Expands Into Significant New Territory
10. NanoBio Expands Drug Development Team for Its Anti-Infective Products
11. BitWine (TM) Nutrition Advisors Network Expands Roster of Licensed Dietitians and Nutritionists
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... BOSTON , Jan. 20, 2017 ... acquisition of Gen9, a pioneer in the synthesis ... Gen9,s unique expertise in assembling pathway-length synthetic DNA ... speed and capacity in the construction of new ... of industries. "Gen9 was founded to ...
(Date:1/19/2017)... and HOUSTON , Jan. ... Prenatal") today announced the formation of its Medical/Clinical ... clinicians and industry veterans who enhance the range ... it accelerates development of its novel prenatal diagnostic ... medical, clinical and strategic guidance for the company,s ...
(Date:1/19/2017)... ANNAPOLIS, Md. and GAITHERSBURG, ... Inc. (NYSE MKT: PIP) and Altimmune, Inc., a ... the signing of a definitive agreement for the ... transaction. Altimmune,s current investors include Novartis Venture Fund, ... company will be a fully-integrated and diversified immunotherapeutics ...
(Date:1/19/2017)... Staten Island, NY (PRWEB) , ... January 19, 2017 , ... ... expand at an exponential rate. The tremendous growth is accounted to two main ... to the table and the expanding network of vendors supplying FireflySci products all around ...
Breaking Biology Technology:
(Date:1/11/2017)... 2017 Intoxalock, a leading ignition interlock provider, ... its patent-pending calibration device. With this new technology, Intoxalock ... upload data logs and process repairs at service center ... "Fighting drunk driving through the application of cutting-edge technologies ... but also for the customer who can get back ...
(Date:1/6/2017)... Calif. , Jan. 5, 2017  Delta ID ... its iris scanning technology for automotive at CESĀ® 2017. ... GNTX ) to demonstrate the use of iris ... identify and authenticate the driver in a car, and ... during the driving experience. Delta ID and ...
(Date:12/22/2016)...  As part of its longstanding mission to improve genetic ... recently released its latest children,s book, titled The ... the topics of inheritance and variation of traits that are ... elementary school classrooms in the US. The ... Ariana Killoran , whose previous book with 23andMe, ...
Breaking Biology News(10 mins):